Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹200 | ₹500 |
Expense Ratio | 2.45 | 1.93 |
NAV | ₹29.84 | ₹437.87 |
Fund Started | 08 Feb 2019 | 04 Jun 1999 |
Fund Size | ₹90.98 Cr | ₹4026.55 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 5.34% | 10.42% |
3 Year | 21.25% | 27.88% |
5 Year | 14.48% | 20.40% |
1 Year
3 Year
5 Year
Equity | 95.59% | 97.60% |
Cash | 4.41% | 2.33% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.10% |
Apollo Hospitals Enterprise Ltd. | 5.54% |
Torrent Pharmaceuticals Ltd. | 5.40% |
Cipla Ltd. | 5.33% |
Divi's Laboratories Ltd. | 4.46% |
Fortis Healthcare Ltd. | 3.97% |
Aurobindo Pharma Ltd. | 3.92% |
Piramal Pharma Ltd. | 3.73% |
Abbott India Ltd. | 3.66% |
Neuland Laboratories Ltd. | 3.52% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.44% |
Divi's Laboratories Ltd. | 7.21% |
Max Healthcare Institute Ltd. | 6.50% |
Cipla Ltd. | 4.63% |
Lonza Group Ag | 4.09% |
Lupin Ltd. | 4.02% |
Gland Pharma Ltd. | 3.59% |
Mankind Pharma Ltd. | 3.57% |
Acutaas Chemicals Ltd. | 3.30% |
Krishna Institute of Medical Sciences Ltd | 3.26% |
Name | Karan Doshi | Tanmaya Desai |
Start Date | 31 Jul 2023 | 27 Jun 2011 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 08 Feb 2019 | 04 Jun 1999 |
Description
Launch Date